Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
- Agenus Inc.
- Applied Genetic Technologies Corp.
- Ariad Pharmaceuticals Inc.
- Can-Fite Biopharma
- Celsion Corp.
- Cesca Therapeutics Inc.
- CTI BioPharma
- Fate Therapeutics Inc.
- Galectin Therapeutics Inc.
- GenVec Inc.
- Keryx Biopharmaceuticals Inc.
- La Jolla Pharmaceutical Co.
- MEI Pharma Inc.
- Neuralstem Inc.
- Novartis AG
- OncoSec Medical Inc.
- Oncothyreon Inc.
- OXiGENE Inc.
- Peregrine Pharmaceuticals Inc.
- RXi Pharmaceuticals Corp.
- Spectrum Pharmaceuticals Inc.
- Sunesis Pharmaceuticals Inc.
- Synta Pharmaceuticals Corp.
- TG Therapeutics Inc.
- Threshold Pharmaceuticals Inc.
- Verastem Inc.
- ZZ-OLD Lion Biotechnologies Inc.
Dr. Reni Benjamin is a managing director and equity research analyst at H.C. Wainwright & Co. His expertise and coverage focuses on companies in the oncology and stem cell sectors. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in ôThe Delivery of Regenerative Medicines and Their Impact on Healthcare,ö has presented at various regional and international conferences, and has been published in peer-reviewed journals. He currently serves on the UAB School of Health Professions' Deans Advisory Board. Prior to joining H.C. Wainwright, Benjamin was a managing director and senior biotechnology analyst at both Burrill Securities and Rodman & Renshaw. He was also an associate analyst at Needham and Company. Benjamin earned his doctorate from the University of Alabama at Birmingham in biochemistry and molecular genetics by discovering and characterizing a novel gene implicated in germ cell development. He earned a bachelor's degree in biology from Allegheny College.
2015 Small-Cap Biotech Watchlist Announced (12/18/14) In its third year, The Life Sciences Report's 2015 Small-Cap Biotech Watchlist currently includes 12 drug development companies selected by leading analysts in the sector. With catalysts on the horizon and pipelines that encompass a variety of indications and innovative platforms, these biotechs are primed to return multiples on investment.
Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners (7/10/14) The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. In this interview with The Life Sciences Report, Benjamin showcases names with powerful platforms and market winds to their backs, which he believes could vigorously multiply investor capital over the next 12ľ18 months.
Regenerative Medicine Finally Gets Some Respect: Reni Benjamin (2/11/14) Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life Sciences Report, Reni Benjamin, managing director and equity research analyst at H.C. Wainwright & Co., talks about two companies with impending catalysts that play on these themes, and offers his take on the prospects for the regenerative medicine sector going forward.
"MSB has a 1,700-patient phase 3 study in progress, evaluating Revascor in congestive heart failureŚclearly a big market." (12/12/13) Mesoblast Ltd. - The Life Sciences Report Interview with Reni Benjamin Moreá>